GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Theratechnologies Inc (TSX:TH) » Definitions » Effective Interest Rate on Debt %

Theratechnologies (TSX:TH) Effective Interest Rate on Debt % : 9.48% (As of Feb. 2025)


View and export this data going back to 1998. Start your Free Trial

What is Theratechnologies Effective Interest Rate on Debt %?

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Theratechnologies's annualized positive value of Interest Expense for the quarter that ended in Feb. 2025 was C$6.4 Mil. Theratechnologies's average total debt for the quarter that ended in Feb. 2025 was C$67.9 Mil. Therefore, Theratechnologies's annualized Effective Interest Rate on Debt % for the quarter that ended in Feb. 2025 was 9.48%.


Theratechnologies Effective Interest Rate on Debt % Historical Data

The historical data trend for Theratechnologies's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theratechnologies Effective Interest Rate on Debt % Chart

Theratechnologies Annual Data
Trend Nov15 Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22 Nov23 Nov24
Effective Interest Rate on Debt %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.05 9.91 10.86 18.18 20.14

Theratechnologies Quarterly Data
May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25
Effective Interest Rate on Debt % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.80 18.31 18.16 18.92 9.48

Competitive Comparison of Theratechnologies's Effective Interest Rate on Debt %

For the Biotechnology subindustry, Theratechnologies's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Theratechnologies's Effective Interest Rate on Debt % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Theratechnologies's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where Theratechnologies's Effective Interest Rate on Debt % falls into.


;
;

Theratechnologies Effective Interest Rate on Debt % Calculation

Theratechnologies's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Nov. 2024 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (A: Nov. 2023 )+Total Debt  (A: Nov. 2024 ))/ count )
=-1  *  -14.558/( (80.827+63.725)/ 2 )
=-1  *  -14.558/72.276
=20.14 %

where

Total Debt  (A: Nov. 2023 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=70.263 + 10.564
=80.827

Total Debt  (A: Nov. 2024 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=58.309 + 5.416
=63.725

Theratechnologies's annualized Effective Interest Rate on Debt % for the quarter that ended in Feb. 2025 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (Q: Nov. 2024 )+Total Debt  (Q: Feb. 2025 ))/ count )
=-1  *  -6.436/( (63.725+71.995)/ 2 )
=-1  *  -6.436/67.86
=9.48 %

where

Total Debt  (Q: Nov. 2024 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=58.309 + 5.416
=63.725

Total Debt  (Q: Feb. 2025 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=65.412 + 6.583
=71.995

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is four times the quarterly (Feb. 2025) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.


Theratechnologies  (TSX:TH) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.


Theratechnologies Effective Interest Rate on Debt % Related Terms

Thank you for viewing the detailed overview of Theratechnologies's Effective Interest Rate on Debt % provided by GuruFocus.com. Please click on the following links to see related term pages.


Theratechnologies Business Description

Industry
Traded in Other Exchanges
Address
2015, rue Peel, 11th Floor, Montreal, QC, CAN, H3A 1T8
Theratechnologies Inc is a specialty pharmaceutical company that addresses the unmet medical needs of HIV patients. It mainly operates in Canada and the United States. The company has two approved products, EGRIFTA marketed in Canada and the United States, and Trogarzo approved for commercialization in the United States. It generates revenue from one customer RxCrossroads, which is domiciled in the United States.
Executives
Dale Weil Director
Joseph Arena Director
Philippe Dubuc Senior Officer
Gérald A. Lacoste Director
Paul Lévesque Senior Officer
Andrew Molson Director
Dawn Svoronos Director
John Leasure Senior Officer
Alain Trudeau Director
Sheila Frame Director
Gary Peter Littlejohn Director
Marie-noël Colussi Senior Officer
Jovan Antunovic Senior Officer
Christian Marsolais Senior Officer
Jocelyn Lafond Senior Officer